Cinzia Baranello
Catholic University of the Sacred Heart
4 Papers
80 Citations
Cinzia Baranello is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: T cell & Cancer. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Cinzia Baranello include The Catholic University of America & Sapienza University of Rome.
Chat about Author
Papers
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.
Alessandra Battaglia,Alexia Buzzonetti,Cinzia Baranello,Gabriella Ferrandina,Enrica Martinelli,Francesco Fanfani,Giovanni Scambia,Andrea Fattorossi,Andrea Fattorossi +8 more
TL;DR: The increased recruitment of suppressor type cells concomitant with the scarcity of cytotoxic type cells suggests that in mTDLN the presence of tumour cells could tip the balance against anti-tumour immune response facilitating the survival of metastatic tumours and possibly contributing to systemic tolerance.
80
The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.
Ombretta Turriziani,P. Pagnotti,Alessandra Pierangeli,Federico Focher,Cinzia Baranello,Francesca Bellomi,Francesca Falasca,Jessica A. Morgan,John D. Schuetz,Guido Antonelli +9 more
TL;DR: Exposure of cells to a combination of NAs is capable of simultaneously affecting more than one target site to confer resistance and that NAs display differing abilities to select cellular resistance mechanisms are shown.
5
Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development.
Alessandra Battaglia,Alexia Buzzonetti,Cinzia Baranello,Mara Fanelli,Marco Fossati,Valentina Catzola,Giovanni Scambia,Andrea Fattorossi +7 more
TL;DR: Present data provide proof‐of‐concept for evaluating a combinatorial approach that would reduce the IL‐2 needed to sustain T‐cell proliferation efficiently, thereby reducing toxicity and controlling a tolerizing mechanism responsible for the contraction of the T‐ cell response.
Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?
Cinzia Baranello,Marisa Mariani,Mirko Andreoli,Mara Fanelli,Enrica Martinelli,Gabriella Ferrandina,Giovanni Scambia,Shohreh Shahabi,Cristiano Ferlini,Cristiano Ferlini +9 more
TL;DR: Although in vitro ADM was a potential factor in biological aggressiveness, this possibility was not confirmed in patients and use of an ADM antagonist would be inappropriate in managing ovarian cancer patients.